| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| John P Buchweitz, Peer W F Karmaus, Kurt J Williams, Jack R Harkema, Norbert E Kaminsk. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol. Journal of leukocyte biology. vol 83. issue 3. 2008-05-14. PMID:18073275. |
targeted deletion of cannabinoid receptors cb1 and cb2 produced enhanced inflammatory responses to influenza a/pr/8/34 in the absence and presence of delta9-tetrahydrocannabinol. |
2008-05-14 |
2023-08-12 |
mouse |
| Estera Páldyová, Erika Bereczki, Miklós Sántha, Tibor Wenger, Anna Borsodi, Sándor Benyh. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochemistry international. vol 52. issue 1-2. 2008-05-05. PMID:17698254. |
noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via cb2 cannabinoid receptors. |
2008-05-05 |
2023-08-12 |
mouse |
| Estera Páldyová, Erika Bereczki, Miklós Sántha, Tibor Wenger, Anna Borsodi, Sándor Benyh. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochemistry international. vol 52. issue 1-2. 2008-05-05. PMID:17698254. |
while noladin ether (ne) demonstrates agonist activity at cb1 cannabinoid receptors, recent data indicate that ne acts as a full agonist at cb2 cannabinoid receptors too. |
2008-05-05 |
2023-08-12 |
mouse |
| Estera Páldyová, Erika Bereczki, Miklós Sántha, Tibor Wenger, Anna Borsodi, Sándor Benyh. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochemistry international. vol 52. issue 1-2. 2008-05-05. PMID:17698254. |
taken together, our data suggest that the ne caused pronounced decrease in the activity of mor is mediated via cb2 cannabinoid receptors. |
2008-05-05 |
2023-08-12 |
mouse |
| Eva de Lago, Javier Fernández-Rui. Cannabinoids and neuroprotection in motor-related disorders. CNS & neurological disorders drug targets. vol 6. issue 6. 2008-05-02. PMID:18220777. |
in both disorders, the key mechanisms involved in the neuroprotection provided by cannabinoids include cannabinoid receptor-independent effects aimed at reducing the oxidative injury, and also cannabinoid 2 receptors (cb2)-mediated effects exerted by regulating the influence of reactive microglia on neuronal homeostasis. |
2008-05-02 |
2023-08-12 |
Not clear |
| Eva de Lago, Javier Fernández-Rui. Cannabinoids and neuroprotection in motor-related disorders. CNS & neurological disorders drug targets. vol 6. issue 6. 2008-05-02. PMID:18220777. |
there is evidence that both cannabinoid 1 receptors (cb1) and cb2 may afford a protective effect in this disease due to their immunomodulatory, anti-inflammatory and anti-excitotoxic properties. |
2008-05-02 |
2023-08-12 |
Not clear |
| Eva de Lago, Javier Fernández-Rui. Cannabinoids and neuroprotection in motor-related disorders. CNS & neurological disorders drug targets. vol 6. issue 6. 2008-05-02. PMID:18220777. |
lastly, neuroprotective effects of cannabinoids exerted by the activation of cb1 but also cb2 receptors have been also identified in amyotrophic lateral sclerosis (als), another degenerative disease characterized by the selective death of spinal motoneurons. |
2008-05-02 |
2023-08-12 |
Not clear |
| F Teixeira-Clerc, B Julien, P Grenard, J Tran Van Nhieu, V Deveaux, C Hezode, A Mallat, S Lotersztaj. [The endocannabinoid system as a novel target for the treatment of liver fibrosis]. Pathologie-biologie. vol 56. issue 1. 2008-04-18. PMID:17412522. |
the cannabinoid system comprises specific g protein-coupled receptors (cb1 and cb2), exogenous (marijuana-derived cannabinoids) and endogenous (endocannabinoids) ligands, and a machinery dedicated to endocannabinoid synthesis and degradation. |
2008-04-18 |
2023-08-12 |
Not clear |
| Monica Bari, Sergio Oddi, Chiara De Simone, Paola Spagnolo, Valeria Gasperi, Natalia Battista, Diego Centonze, Mauro Maccarron. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology. vol 54. issue 1. 2008-04-18. PMID:17714745. |
type-1 (cb1) and type-2 (cb2) cannabinoid receptors belong to the rhodopsin family of g protein-coupled receptors, and are activated by endogenous lipids termed "endocannabinoids". |
2008-04-18 |
2023-08-12 |
Not clear |
| Amir Reza Hajrasouliha, Sina Tavakoli, Mehdi Ghasemi, Pejman Jabehdar-Maralani, Hamed Sadeghipour, Farzad Ebrahimi, Ahmad Reza Dehpou. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. European journal of pharmacology. vol 579. issue 1-3. 2008-04-15. PMID:17950273. |
endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid cb2 receptors in the rat heart. |
2008-04-15 |
2023-08-12 |
rat |
| Vincenzo Micale, Carmen Mazzola, Filippo Drag. Endocannabinoids and neurodegenerative diseases. Pharmacological research. vol 56. issue 5. 2008-04-08. PMID:17950616. |
the cannabinoid cb1 and cb2 receptors, the endogenous endocannabinoid (ec) ligands anandamide (aea) and 2-arachidonylethanolamide, and the degradative enzymes fatty acid amide hydrolase (faah) and monoglyceride lipase (ml) are key elements of the ec system implicated in different physiological functions including cognition, motor activity and immune responses. |
2008-04-08 |
2023-08-12 |
Not clear |
| Vincenzo Micale, Carmen Mazzola, Filippo Drag. Endocannabinoids and neurodegenerative diseases. Pharmacological research. vol 56. issue 5. 2008-04-08. PMID:17950616. |
decrease of neuronal cannabinoid cb1 receptors, increase of glial cannabinoid cb2 receptors and over-expression of faah in astrocytes) in experimental models of ad as well as in post-mortem brain tissue of ad patients, suggesting its possible role in inflammatory processes and in neuroprotection. |
2008-04-08 |
2023-08-12 |
Not clear |
| Vincenzo Micale, Carmen Mazzola, Filippo Drag. Endocannabinoids and neurodegenerative diseases. Pharmacological research. vol 56. issue 5. 2008-04-08. PMID:17950616. |
we focus on the effects of compounds modulating the ec system (agonists/antagonists of cannabinoid cb1 and cb2 receptors, or inhibitors of ecs metabolism processes) on the symptoms and/or progression of neurodegenerative diseases. |
2008-04-08 |
2023-08-12 |
Not clear |
| Christine Börner, Andrea Bedini, Volker Höllt, Jürgen Krau. Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. Molecular pharmacology. vol 73. issue 3. 2008-04-07. PMID:18156315. |
the majority of effects of cannabinoids are mediated by the two receptors cb1 and cb2. |
2008-04-07 |
2023-08-12 |
human |
| Afa K Palu, Anne Hirazumi Kim, Brett J West, Shixin Deng, Jarakae Jensen, Leland Whit. The effects of Morinda citrifolia L. (noni) on the immune system: its molecular mechanisms of action. Journal of ethnopharmacology. vol 115. issue 3. 2008-04-03. PMID:18063495. |
in vitro, tahitian noni juice (tnj) and noni fruit juice concentrates (nfjc) (1, 5mg/ml) potently activate cannabinoid 2 (cb2), but inhibit cannabinoid 1 (cb1) receptors in a concentration-dependant manner. |
2008-04-03 |
2023-08-12 |
mouse |
| M Maccarron. CB2 receptors in reproduction. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828289. |
this review will focus on the involvement of type-2 cannabinoid (cb2) receptors in reproductive biology, covering both the male and female sides. |
2008-04-02 |
2023-08-12 |
mouse |
| M Maccarron. CB2 receptors in reproduction. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828289. |
it will also discuss the potential relevance of the immunological activity of cb2 at the maternal/foetal interface, as well as the distinctiveness of cb2 versus type-1 cannabinoid (cb1) receptors that might be exploited for a receptor subtype-specific regulation of fertility. |
2008-04-02 |
2023-08-12 |
mouse |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
the diverse cb1 and cb2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. |
2008-04-02 |
2023-08-12 |
Not clear |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
this review focuses on the manner with which three of these compounds, (-)-trans-delta9-tetrahydrocannabinol (delta9-thc), (-)-cannabidiol (cbd) and (-)-trans-delta9-tetrahydrocannabivarin (delta9-thcv), interact with cannabinoid cb1 and cb2 receptors. |
2008-04-02 |
2023-08-12 |
Not clear |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
delta9-thc, the main psychotropic constituent of cannabis, is a cb1 and cb2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by the expression level and signalling efficiency of cannabinoid receptors and by ongoing endogenous cannabinoid release. |
2008-04-02 |
2023-08-12 |
Not clear |